Established · publishing since 1990Rising activity
Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysEstrogen and related hormone effects
Publications
215
Citations
5,513
Est. group size
~13
Recurring co-author estimate
Active years
37
Publishing since 1990
In context
Among 4,953 established Medicine PIs within our index
Citations: 5,513p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 21.0p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~9 · 5% small-team papers (≤3 authors) · across 30 venues
Publication cadence
Publications per year over the last 10 years — averaging 21.0/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Peritoneal Carcinomatosis: An Unexpected Differential
Journal of Gynecology and Reproductive Health · 2026
- Figure S6 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S3 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S2 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S1 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S5 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S4 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Figure S7 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2026
- Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Nature Communications · 2025
- The UMPIRE study: A first‐in‐human multicenter trial of bilateral subscalp monitoring for epileptic seizure detection
Epilepsia · 2025
- Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
Cancer Research · 2025
- Effects of complement C3/C3b inhibition on control of malignant effusions and neutrophil phenotypes in patients with recurrent epithelial ovarian cancer: Interim analysis of a phase 2 clinical trial
Immunobiology · 2025
- Figure S1 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2025
- Supplemental Figure Legends from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2025
- Figure S6 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
2025
Publishes in
- Gynecologic Oncology×25
- Clinical Cancer Research×9
- Cancer Research×5
- Journal of the National Comprehensive Cancer Network×4
- JCI Insight×3
Similar researchers
By research-topic overlap
- Leigh Pearce
Medicine · University of Michigan
- Richard L. Carpenter
Medicine · Indiana University
- Sreeja C. Sekhar
Medicine · University of Michigan
- Harrison Ball
Medicine · University of Michigan
- Yali Zhai
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile